Literature DB >> 18326856

Activity of BAL 4815 against filamentous fungi.

C Martín de la Escalera1, A I Aller, E López-Oviedo, A Romero, A I Martos, E Cantón, J Pemán, P García Martos, E Martín-Mazuelos.   

Abstract

OBJECTIVES: BAL 4815 is a new antifungal drug and it is the active component of the antifungal triazole BAL 8557 (the water-soluble precursor). We studied the in vitro fungistatic and fungicidal activities of BAL 4815 against 103 clinical isolates of filamentous fungi, including 51 isolates of Aspergillus spp. and 52 isolates of non-Aspergillus filamentous fungi.
METHODS: We evaluated the in vitro activity of BAL 4815 against 51 isolates of Aspergillus spp., 20 isolates of dematiaceous fungi, 18 isolates of hyaline Hyphomycetes and 14 isolates of Zygomycetes. MICs were determined following the CLSI M38-A broth microdilution method, using RPMI 1640 medium buffered to pH 7.0 with MOPS. Microdilution plates were incubated at 35 degrees C and read at 24 and 48 h (Mucorales were read at 24 h). Minimal fungicidal concentrations were also determined.
RESULTS: For all isolates, geometric mean MICs, MIC(50)s, MIC(90)s and MIC ranges (mg/L) were: Aspergillus spp., 1.67, 2, 4 and 0.5-4; dematiaceous fungi, 1.62, 1, >8 and 0.03 to >8; hyaline Hyphomycetes, 2.41, 2, >8 and 0.03 to >8; and Zygomycetes, 6.81, 8, >8 and 0.03 to >8. Differences in susceptibility between genera were noted. Scedosporium prolificans, Fusarium spp., Mucor spp. and Rhizopus spp. (MIC(90) > 8 mg/L) were less susceptible than Aspergillus spp. (MIC(90) = 4 mg/L).
CONCLUSIONS: BAL 4815 has excellent in vitro activity against Aspergillus spp. and variable activity against other filamentous fungi.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18326856     DOI: 10.1093/jac/dkn076

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.758


  6 in total

1.  A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.

Authors:  J Viljoen; N Azie; A-H Schmitt-Hoffmann; M Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

2.  Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Jacques F Meis; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

3.  Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.

Authors:  Teclegiorgis Gebremariam; Nathan P Wiederhold; Abdullah Alqarihi; Priya Uppuluri; Nkechi Azie; John E Edwards; Ashraf S Ibrahim
Journal:  J Antimicrob Chemother       Date:  2016-10-24       Impact factor: 5.790

4.  Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.

Authors:  A Schmitt-Hoffmann; B Roos; J Spickermann; M Heep; E Peterfaí; D J Edwards; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  2009-08-10       Impact factor: 5.191

5.  Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern.

Authors:  A Chakrabarti; M R Shivaprakash; I Curfs-Breuker; A Baghela; C H Klaassen; J F Meis
Journal:  J Clin Microbiol       Date:  2010-09-29       Impact factor: 5.948

6.  In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  Susanne Perkhofer; Veronika Lechner; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2009-01-21       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.